Comparison · NCT02446899-22a460bd
Anifrolumab 300 mg vs Placebo: Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Anifrolumab 300 mg vs Placebo: Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day. Trial comparisons, record NCT02446899-22a460bd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02446899-22a460bd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.517 | 0.414 | 0.619 | wilson | |
| Risk in group 2 | 0.301 | 0.213 | 0.407 | wilson | |
| Risk difference, group 1 minus group 2 | 0.216 | 0.0681 | 0.351 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.72 | 1.17 | 2.52 | log | |
| Odds ratio, group 1 over group 2 | 2.49 | 1.32 | 4.67 | log | |
| Number needed to treat, for one more participant with the outcome on Anifrolumab 300 mg than on Placebo | 4.63 | 2.85 | 14.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Anifrolumab 300 mg | Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses). | 45 | 87 | OG000 |
| Group 2 | Placebo | Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses). | 25 | 83 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day
- Description
Maintained OCS reduction was defined by meeting all of the following criteria:~* Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40~* Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52~* No discontinuation of investigational product~* No use of restricted medications beyond the protocol allowed threshold before assessment
- Time frame
- Week 40; Week 52
- Population
- Full Analysis Set: All participants who were randomized and received at least one dose of study drug, who had a baseline OCS dose of ≥10 mg/day.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
- NCT number
- NCT02446899
- Phases
- PHASE3
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2020-03-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02446899?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02446899-22a460bd